*Center INSERM U897, Epidémiologie Biostatistiques, Bordeaux, France; †Université Bordeaux, ISPED, Center INSERM U897, Epidémiologie Biostatistiques, Bordeaux, France; ‡Université de Cocody, Abidjan, Côte d'Ivoire; §CePReF, ACONDA, Abidjan Côte d'Ivoire; ‖Department of Pediatrics, Cocody University Hospital, Abidjan, Côte d'Ivoire; and ¶Massachusetts General Hospital, Boston, MA.
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e95-103. doi: 10.1097/QAI.0b013e3182a4ea6f.
We describe severe morbidity and health care resource utilization (HCRU) among HIV-infected children on antiretroviral therapy (ART) in Abidjan, Côte d'Ivoire.
All HIV-infected children enrolled in an HIV-care program (2004-2009) were eligible for ART initiation until database closeout, death, ART interruption, or loss to follow-up. We calculated incidence rates (IRs) of density per 100 child-years (CYs) for severe morbidity, HCRU (outpatient care and inpatient care), and associated factors using frailty models with a Weibull distribution.
Of 332 children with a median age of 5.7 years and median follow-up of 2.5 years, 65.4% were severely immunodeficient by World Health Organization (WHO) criteria, and all received cotrimoxazole prophylaxis. We recorded 464 clinical events in 228 children; the overall IR was 57.6/100 CYs [95% confidence interval (CI): 52.1 to 62.5]. Severe morbidity was more frequent in children on protease inhibitor (PI)-based ART compared to those on other regimens [adjusted hazards ratio (aHR): 1.83; 95% CI: 1.35 to 2.47] and to those moderately/severely immunodeficient compared to those not (aHR: 1.57; 95% CI: 1.13 to 2.18 and aHR: 2.53; 95% CI: 1.81 to 3.55, respectively). Of the 464 events, 371 (80%) led to outpatient care (IR: 45.6/100 CYs) and 164 (35%) to inpatient care (IR: 20.2/100 CYs). In adjusted analyses, outpatient care was significantly less frequent in children older than 10 years compared with children younger than 2 years (aHR: 0.49; 95% CI: 0.31 to 0.78) and in those living furthest from clinics compared with those living closest (aHR: 0.65; 95% CI: 0.47 to 0.90). Both inpatient and outpatient HCRU were negatively associated with cotrimoxazole prophylaxis.
Despite ART, HIV-infected children still require substantial utilization of health care services.
我们描述了在科特迪瓦阿比让接受抗逆转录病毒治疗 (ART) 的 HIV 感染儿童的严重发病率和卫生保健资源利用 (HCRU)。
所有在艾滋病毒护理方案中登记的 HIV 感染儿童(2004-2009 年),只要数据库关闭、死亡、ART 中断或失访前,都有资格开始接受 ART。我们使用 Weibull 分布的脆弱性模型,计算了严重发病率、HCRU(门诊护理和住院护理)和相关因素的每 100 儿童年 (CY) 的发生率 (IR)。
332 名儿童的中位年龄为 5.7 岁,中位随访时间为 2.5 年,其中 65.4% 的儿童按世界卫生组织 (WHO) 标准严重免疫缺陷,所有儿童均接受复方新诺明预防。在 228 名儿童中记录了 464 例临床事件;总体发病率为 57.6/100 CY[95%置信区间 (CI): 52.1 至 62.5]。与接受其他方案治疗的儿童相比,接受蛋白酶抑制剂 (PI) 为基础的 ART 治疗的儿童更易发生严重发病率(校正后的危险比[aHR]:1.83;95%CI:1.35 至 2.47),与中度/重度免疫缺陷的儿童相比,无免疫缺陷的儿童更易发生严重发病率(aHR:1.57;95%CI:1.13 至 2.18 和 aHR:2.53;95%CI:1.81 至 3.55)。在 464 次事件中,371 次(80%)导致门诊护理(IR:45.6/100 CY),164 次(35%)导致住院护理(IR:20.2/100 CY)。在调整后的分析中,与年龄小于 2 岁的儿童相比,年龄大于 10 岁的儿童的门诊护理(aHR:0.49;95%CI:0.31 至 0.78)和距离诊所最远的儿童的门诊护理(aHR:0.65;95%CI:0.47 至 0.90)显著较少。住院和门诊 HCRU 均与复方新诺明预防呈负相关。
尽管接受了抗逆转录病毒治疗,HIV 感染儿童仍需大量使用卫生保健服务。